Biostatistix

biostatistix identifies the mechanisms of action (moa) for new chemical entities and repositions approved drugs using a cost-efficient proprietary platform and process that speeds up "go/no go" decision-making and saves r&d money. the molecular profile matcher platform has already successfully identified the moa for two compounds currently developed by our partner, critical outcome technologies of london ontario (tsx cot-v ) for the treatment of small cell lung cancer and colon cancer. we provide full experimental validation so that novel targets and highly efficient compounds receive full attention while redundant compounds are eliminated.